Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOSNASDAQ:ASRTNASDAQ:CTOROTCMKTS:SRNEQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.02-2.4%$1.04$0.86▼$3.60$62.09M0.09291,177 shs106,444 shsASRTAssertio$0.67-0.5%$0.64$0.51▼$1.80$63.89M0.32664,098 shs35,145 shsCTORCitius Oncology$0.93+1.4%$0.80$0.55▼$4.42$66.40M-0.171.05 million shs18,606 shsSRNEQSorrento Therapeutics$0.00$0.00$0.00▼$0.42$717K2.25511,766 shs7,207 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals+4.00%+1.96%-3.70%-15.45%-62.18%ASRTAssertio+2.04%-1.47%+3.12%-18.02%-33.00%CTORCitius Oncology+2.80%+2.81%-1.08%-11.16%+91,499,900.00%SRNEQSorrento Therapeutics0.00%0.00%+44.44%+85.71%-88.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABOSAcumen Pharmaceuticals2.8113 of 5 stars3.72.00.00.03.71.70.6ASRTAssertio2.0997 of 5 stars3.50.00.00.03.30.81.3CTORCitius OncologyN/AN/AN/AN/AN/AN/AN/AN/ASRNEQSorrento TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 3.33Buy$7.33622.50% UpsideASRTAssertio 3.00Buy$2.75312.29% UpsideCTORCitius Oncology 2.00Hold$3.00223.28% UpsideSRNEQSorrento Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SRNEQ, ASRT, CTOR, and ABOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025CTORCitius OncologyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold5/23/2025CTORCitius OncologyMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/19/2025ASRTAssertioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50 ➝ $3.505/13/2025ASRTAssertioAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/28/2025ABOSAcumen PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.003/28/2025ABOSAcumen PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $11.003/19/2025ASRTAssertioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.503/14/2025ASRTAssertioIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$1.75(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$4.61 per shareN/AASRTAssertio$119.00M0.54$0.60 per share1.12$1.46 per share0.46CTORCitius OncologyN/AN/AN/AN/A($0.22) per shareN/ASRNEQSorrento Therapeutics$62.84M0.01N/AN/A($0.05) per share-0.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$52.37M-$1.94N/AN/AN/AN/A-32.99%-27.99%8/12/2025 (Estimated)ASRTAssertio-$331.94M-$0.32N/A22.233.25-54.46%3.79%1.81%8/6/2025 (Estimated)CTORCitius Oncology-$21.15MN/A0.00∞N/AN/A-43.67%-9.74%N/ASRNEQSorrento Therapeutics-$572.84MN/A0.00∞N/AN/AN/AN/AN/ALatest SRNEQ, ASRT, CTOR, and ABOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025CTORCitius Oncology-$0.09-$0.11-$0.02-$0.11$5.74 millionN/A5/13/2025Q1 2025ABOSAcumen Pharmaceuticals-$0.56-$0.48+$0.08-$0.48N/AN/A5/12/2025Q1 2025ASRTAssertio-$0.06-$0.14-$0.08-$0.14$27.52 million$26.49 million3/27/2025Q4 2024ABOSAcumen Pharmaceuticals-$0.47-$0.62-$0.15-$0.62N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/AASRTAssertioN/AN/AN/AN/AN/ACTORCitius OncologyN/AN/AN/AN/AN/ASRNEQSorrento TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.1410.4310.43ASRTAssertio0.302.011.57CTORCitius Oncology0.080.340.08SRNEQSorrento TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%ASRTAssertio48.96%CTORCitius Oncology70.52%SRNEQSorrento Therapeutics0.02%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals9.30%ASRTAssertio4.00%CTORCitius Oncology4.57%SRNEQSorrento Therapeutics2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2060.57 million55.81 millionOptionableASRTAssertio2095.78 million92.42 millionOptionableCTORCitius OncologyN/A71.55 million55.17 millionN/ASRNEQSorrento Therapeutics800551.28 million536.95 millionNot OptionableSRNEQ, ASRT, CTOR, and ABOS HeadlinesRecent News About These CompaniesSorrento Therapeutics Restructuring Chief Hosted Party for Judges Who Later Oversaw Its LiquidationSeptember 3, 2024 | wsj.comSorrento, Naples, Italy Weather Conditionsstar_ratehomeAugust 29, 2024 | wunderground.comSorrento, British Columbia, Canada 10-Day Weather Forecaststar_ratehomeAugust 26, 2024 | wunderground.comSorrento Announces New Board MemberAugust 22, 2024 | br.advfn.comSorrento wins DoJ’s venue-based challenge to bankruptcy filingMarch 12, 2024 | msn.comSorrento’s Bankruptcy Venue Action Is ‘Unprecedented,’ DOJ SaysMarch 9, 2024 | news.bloomberglaw.comLatham, Jackson Walker avoid sanctions over bankruptcy forum shopping disputeFebruary 29, 2024 | reuters.comVirpax reaches deal to settle litigation with Sorrento Therapeutics, Scilex PharmaceuticalsFebruary 27, 2024 | bizjournals.comSorrento Therapeutics Stock (OTC:SRNEQ) Dividends: History, Yield and DatesFebruary 22, 2024 | benzinga.comSorrento faked venue in bankruptcy filing, Justice Department saysFebruary 21, 2024 | msn.comSorrento Therapeutics Inc (SRNEQ) Earnings Dates & ReportsNovember 18, 2023 | investing.comScilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate ...October 7, 2023 | bakersfield.comScilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate Potential Naked Short Selling, Short Positions, Stock Lending Program Activities and Market Manipulation of Its Stock PriceOctober 7, 2023 | finance.yahoo.comScilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted ...October 4, 2023 | bakersfield.comScilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding CompanyOctober 3, 2023 | finance.yahoo.comScilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.September 21, 2023 | finance.yahoo.comScilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to Severe Acute Lower Back Pain (LBP)September 14, 2023 | finance.yahoo.comScilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful BidderSeptember 13, 2023 | finance.yahoo.comSorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19September 12, 2023 | finance.yahoo.comScilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently Available InformationSeptember 11, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyTurbulence for Joby Shares: What's Behind the Recent Dip?By Jeffrey Neal Johnson | May 22, 2025View Turbulence for Joby Shares: What's Behind the Recent Dip?3 Top-Rated Energy Companies Staging Strong RecoveriesBy Nathan Reiff | June 2, 2025View 3 Top-Rated Energy Companies Staging Strong RecoveriesGoogle Is Betting Big on Nuclear Reactors—Should You?By Dan Schmidt | May 9, 2025View Google Is Betting Big on Nuclear Reactors—Should You?SRNEQ, ASRT, CTOR, and ABOS Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$1.01 -0.03 (-2.40%) As of 12:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Assertio NASDAQ:ASRT$0.67 0.00 (-0.46%) As of 12:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Citius Oncology NASDAQ:CTOR$0.93 +0.01 (+1.42%) As of 12:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Sorrento Therapeutics OTCMKTS:SRNEQ$0.0013 0.00 (0.00%) As of 06/2/2025Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Tesla’s Lofty 200 P/E Could Mean More Upside Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
